Secretion of galectin-3 into the ECM by tumour cells bound the inflammatory cytokine CXCL9, effectively negating the development of chemokine gradients that would otherwise guide T-cells towards the tumour cells [120]. This evidence concerns the gene CXCL9 and neoplasm.